Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance Program-Reference-Cited by-同舟云学术

Safety Experience With Bosentan in 146 Children 2–11 Years Old With Pulmonary Arterial Hypertension: Results from the European Postmarketing Surveillance Program

Published:2008-08 Issue:2 Volume:64 Page:200-204
ISSN:0031-3998
Container-title:Pediatric Research
language:
Short-container-title:Pediatr Res

Author:

Beghetti Maurice,Hoeper Marius M,Kiely David G,Carlsen Joern,Schwierin Barbara,Segal Eleanor S,Humbert Marc

Publisher

Springer Science and Business Media LLC

Subject

Pediatrics, Perinatology and Child Health

Reference19 articles.

1. Primary Pulmonary Hypertension

2. Cellular and molecular pathobiology of pulmonary arterial hypertension

3. Pulmonary arterial hypertension in children

4. Outcomes in Children With Idiopathic Pulmonary Arterial Hypertension

5. Epoprostenol treatment in children with severe pulmonary hypertension

Cited by 95 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeted Therapies for Neonatal Pulmonary Hypertension: Beyond Nitric Oxide;Clinics in Perinatology;2023-12

2. Bosentan attenuates sickle cell disease erythrocyte HbS polymerization and impaired deformability induced by endothelin-1;Canadian Journal of Physiology and Pharmacology;2023-12-01

3. Bosentan attenuates sickle cell disease erythrocyte HbS polymerization and impaired deformability induced by endothelin-1;CAN J PHYSIOL PHARM;2023

4. Pediatric Population Pharmacokinetic Modeling and Exposure–Response Analysis of Ambrisentan in Pulmonary Arterial Hypertension and Comparison With Adult Data;The Journal of Clinical Pharmacology;2023-01-29

5. Treatment of pulmonary arterial hypertension in children;Cardiovascular Diagnosis and Therapy;2021-08